Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 2/20 | 0.36 |
| ▸ | FABP4 | P15090 | 6/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 6/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168380 | 0.89 | FKBP1A (0.35) | FKBP1AF2FABP4FABP5ALDH1A1 | |
| SCHEMBL21168295 | 0.87 | ACE (0.41) | — | |
| SCHEMBL21168296 | 0.87 | ACE (0.41) | — | |
| SCHEMBL21168327 | 0.87 | ACE (0.39) | FKBP1AFABP4FABP5ALDH1A1CYP3A4 | |
| SCHEMBL21168286 | 0.86 | ACE (0.40) | — | |
| SCHEMBL21168276 | 0.86 | ACE (0.35) | FKBP1AF2FABP4FABP5ALDH1A1 | |
| SCHEMBL21168332 | 0.86 | ACE (0.35) | FKBP1AF2FABP4FABP5ALDH1A1 | |
| SCHEMBL21168279 | 0.85 | ACE (0.43) | FKBP1AFABP4FABP5ALDH1A1CYP3A4 | |
| SCHEMBL21168328 | 0.85 | ACE (0.43) | FKBP1AFABP4FABP5ALDH1A1CYP3A4 | |
| SCHEMBL21168289 | 0.85 | FABP4 (0.32) | FKBP1AFABP4FABP5DPP4THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220241248-A1 | COMBINATION OF SMALL MOLECULE CD-47 INHIBITORS WITH OTHER ANTI-CANCER AGENTS | CD47, CD63, CD99 | FKBP1A 2991/4885F2 4779/4885FABP4 4619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.